Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.

Single-dose mass drug administration of azithromycin (AZT) is underway to eliminate trachoma worldwide. Studies in Ethiopia showed a reduction in all-cause childhood deaths after administration. To examine the effect of single-dose AZ MDA on prevalent malaria infections in a large prospective cohort of children and parents in Dodoma Province, Tanzania, we quantified the temporal prevalence of malaria parasitemia by real-time PCR for 6 months after single-dose AZT. In the first month after treatment but not in subsequent months, Plasmodium falciparum infections were reduced by 73% (95% CI 43%-89%) in treatment versus control villages and differences remained significant (p = 0.00497) in multivariate models with village-level random effects. Genetic sequencing of P. falciparum ribosomal L4 protein showed no mutations associated with AZT resistance. AZT mass drug administration caused a transient, 1-month antimalarial effect without selecting for P. falciparum ribosomal L4 resistance mutations in a region with a 10-year history of treating trachoma with this drug.

Association of visual field loss and mobility performance in older adults: Salisbury Eye Evaluation Study.

PURPOSE: To determine the association between visual field loss and orientation and mobility (O&M) performance in a population-based sample of older adults and to identify the specific regions of the visual field that are most strongly associated with O&M performance. METHODS: A population-based sample of 1504 persons between the ages of 72 to 92 was enrolled in the third round of Salisbury Eye Evaluation. Monocular visual fields (60 degrees radius) were tested with the 81-point, single intensity (24 dB) screening test strategy on the Humphrey Field Analyzer. Binocular visual fields were estimated from a combination of the monocular fields. The number of points missed was calculated for the overall visual field and for 3 non-overlapping regions: central (< or = 20 degrees radius), upper- and lower-peripheral visual fields. Orientation and mobility performance was evaluated by walking speed, number of bumps, and number of orientation errors on a circuitous, 32.8-m course seeded with obstacles. Log-linear regressions and linear regressions, adjusting for age, gender, body mass, height, cognitive and general health status, were performed. RESULTS: Loss in the overall visual field was associated with an increase in the number of bumps and decrease in walking speed. Visual field loss was not associated with the number of orientation errors. Out of the three visual field sub-regions that we tested, in terms of percentage of loss, the central and lower peripheral regions showed comparable decrements in walking speed and the central region was most strongly associated with number of bumps. CONCLUSIONS: The loss in visual field, which occurs with aging, is associated with a decline in mobility performance. Walking speed decreases, and the number of bumps into obstacles increases, with decreases in the visual field. The number of orientation errors is not associated with the loss in visual field that occurs with aging.

Prevalence of open-angle glaucoma among adults in the United States.

OBJECTIVE: To estimate the prevalence and distribution of open-angle glaucoma (OAG) in the United States by age, race/ethnicity, and gender. METHODS: Summary prevalence estimates of OAG were prepared separately for black, Hispanic, and white subjects in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US census data and to projected US population figures for 2020 to estimate the number of the US population with OAG. RESULTS: The overall prevalence of OAG in the US population 40 years and older is estimated to be 1.86% (95% confidence interval, 1.75%-1.96%), with 1.57 million white and 398 000 black persons affected. After applying race-, age-, and gender-specific rates to the US population as determined in the 2000 US census, we estimated that OAG affects 2.22 million US citizens. Owing to the rapidly aging population, the number with OAG will increase by 50% to 3.36 million in 2020. Black subjects had almost 3 times the age-adjusted prevalence of glaucoma than white subjects. CONCLUSIONS: Open-angle glaucoma affects more than 2 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to more than 3 million by 2020.